OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Further positive data for Mologic COVID-19 lateral flow antigen test
Mologic test shows high diagnostic accuracy (specificity and sensitivity)
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the Mologic COVID-19 lateral flow antigen test has been independently verified in a 665-person study in Germany by FIND a global not-for-profit foundation. The test was shown to demonstrate best-in-class performance with 100% specificity and 96.4% sensitivity (Cycle threshold <25) compared with laboratory PCR testing.
FIND (www.finddx.org), is a World Health Organization collaborating centre for laboratory strengthening and diagnostic technology evaluation and seeks to find diagnostic solutions to overcome diseases of poverty in lower- and middle-income countries.
The report is available to read here:
https://www.finddx.org/wp-content/uploads/2021/04/Mologic_Ag-Public-Report_v1-20210423.pdf
Omega has CE-Marked the Mologic lateral flow antigen test for COVID-19 and has launched the test for professional-use under Omega's VISITECT® brand. The VISITECT® COVID-19 Antigen test provides healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs in 10 minutes.
For further information please visit: VISITECT® COVID-19 Antigen Test | Omega Diagnostics
Colin King, CEO of Omega, commented: "This is great news for the Mologic test, which we are now producing under our VISITECT brand. It is significant that the test has been shown to have high diagnostic accuracy on self-collected swab specimens. Rapid diagnostic tests play a crucial role in breaking the spread of infection in the community and we are delighted to be a leading manufacturer of these home-grown tests."
Contacts:
| Omega Diagnostics Group PLC | |
| Colin King, Chief Executive | via Walbrook PR |
| Kieron Harbinson, Group Finance Director | |
| | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley (Corporate Finance) | |
| Alice Lane (ECM) | |
| | |
| Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Cawthorne | Mob: 07584 391 303 |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
